SCHEMBL3973547

SCHEMBL3973547

O=C1Nc2cc(Cl)ccc2C1(O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
CASP6 P55212 1/20 0.49
CYP2A6 P11509 1/20 0.42
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
BRD4 O60885 2/20 0.39
TP53 P04637 3/20 0.38
MDM2 Q00987 3/20 0.38
PIM1 P11309 1/20 0.38
DHFR P00374 1/20 0.38
TYMS P04818 1/20 0.38
IDO1 P14902 1/20 0.37
GHSR Q92847 1/20 0.37
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
KDM1A O60341 1/20 0.36
RCOR1 Q9UKL0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2496770 0.89 POLB (0.49) POLBCASP6CYP2A6KMT2AMEN1
SCHEMBL24281862 0.84 POLB (0.48) POLBCASP6KMT2AMEN1BRD4
SCHEMBL3969045 0.84 BRD4 (0.49) POLBCASP6KMT2AMEN1BRD4
SCHEMBL3966468 0.83 BRD4 (0.52) POLBCASP6KMT2AMEN1BRD4
SCHEMBL6180564 0.80 ALDH1A1 (0.46) POLBCASP6TP53GHSRMAPT
SCHEMBL3968785 0.80 MEN1 (0.53) POLBCASP6KMT2AMEN1BRD4
SCHEMBL3971829 0.80 POLB (0.56) POLBCASP6KMT2AMEN1BRD4
SCHEMBL3967991 0.78 ADAMTS5 (0.52) POLBCASP6KMT2ABRD4TP53
SCHEMBL13658982 0.78 CYP2A6 (0.52) CYP2A6DHFRTYMSMAPTKDM1A
SCHEMBL3969763 0.78 TP53 (0.62) POLBCASP6KMT2ABRD4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 POLB 3082/4885CASP6 3177/4885CYP2A6 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.